Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
Fong Y, Dang L, Zhang B, Fintzi J, Chen S, Wang J, Rouphael NG, Branche AR, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Yu C, Magaret CA, Molitor C, Borate B, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Mu J, Makowski M, Makhene MK, Nayak SU, Roberts PC, Follmann D, Gilbert PB; Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team.
Fong Y, et al. Among authors: walter eb.
Clin Infect Dis. 2024 Sep 26:ciae465. doi: 10.1093/cid/ciae465. Online ahead of print.
Clin Infect Dis. 2024.
PMID: 39325506